8-K: Achieve Life Sciences Announces Positive Safety Data for Cytisinicline in ORCA-OL Trial, Reaffirms Q2 2025 NDA Submission

Achieve Life Sciences reports positive safety data from the ORCA-OL trial for cytisinicline, with no unexpected adverse events, and reiterates its plan to submit a New Drug Application (NDA) in Q2 2025.

Summary

• Achieve Life Sciences announced positive results from the second Data Safety Monitoring Committee (DSMC) review of the ORCA-OL trial.
• The DSMC found no unexpected treatment-related adverse events and reported excellent participant adherence to cytisinicline medication.
• Safety data remained consistent with previous findings, allowing the study to continue as planned.
• Achieve remains on track to submit its New Drug Application (NDA) for cytisinicline in Q2 2025.
• The ORCA-OL trial is designed to meet the FDA's long-term exposure safety data requirements, including six-month data from at least 300 participants and one-year data from at least 100 participants.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with successful trial reviews and adherence to the NDA submission timeline. The absence of identified safety concerns further contributes to a favorable sentiment.

Positives

• The DSMC identified no unexpected treatment-related adverse events, indicating a favorable safety profile for cytisinicline.
• Excellent participant adherence suggests the treatment is well-tolerated.
• Achieve remains on track for its planned NDA submission in Q2 2025, moving closer to potential FDA approval.
• The ORCA-OL trial has met key milestones, including enrollment completion and achieving the target number of participants with six months of treatment.

Risks

• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• These risks include the possibility that cytisinicline may not demonstrate the expected benefits, Achieve may not be able to obtain additional financing, and cytisinicline may not receive regulatory approval or be successfully commercialized.

Future Outlook

Achieve Life Sciences anticipates submitting its New Drug Application (NDA) for cytisinicline in Q2 2025 and remains focused on addressing the public health crisis of nicotine dependence.

Management Comments

• Cindy Jacobs, PhD, MD, President and Chief Medical Officer of Achieve, stated that the DSMC review confirms previous findings regarding the overall safety of cytisinicline.
• Rick Stewart, Chief Executive Officer of Achieve, added that Achieve remains on track with its expected NDA submission next quarter for cytisinicline as a treatment of nicotine dependence for smoking cessation.

Industry Context

Achieve Life Sciences is developing cytisinicline as a potential new treatment for nicotine dependence, addressing a significant public health issue with limited recent innovation in prescription treatments.

Comparison to Industry Standards

• The document mentions that cytisinicline, if approved, would be the first new prescription treatment for smoking cessation in nearly 20 years.
• This highlights a gap in the market and suggests that cytisinicline could compete with existing treatments like nicotine replacement therapy (NRT), bupropion (Zyban), and varenicline (Chantix).
• The success of cytisinicline will depend on its efficacy, safety profile, and market access compared to these established options.

Stakeholder Impact

• Positive safety data and progress towards NDA submission are likely to be viewed favorably by shareholders.
• If approved, cytisinicline could provide physicians and smokers with a new tool to stop smoking, addressing a significant public health crisis.
• The development and commercialization of cytisinicline could create new job opportunities.

Next Steps

• Achieve plans to submit its New Drug Application (NDA) for cytisinicline in Q2 2025.
• The FDA will review the NDA, including long-term safety data from the ORCA-OL trial.
• Achieve will continue to evaluate longer-term safety exposure of cytisinicline in the ORCA-OL trial.

Key Dates